UCB Articles
UCB confirms Zyrtec sales performance
24 January 2005
UCB and Combinature form alliance
24 January 2005
New directorships for Goran Ando
10 January 2005
UCB hikes R&D budget nearly 60%
10 January 2005
UCB submits pediatric and IV Keppra filings
10 January 2005
UCB opens new $40M Keppra facility
20 December 2004
Stock Commentary - New York
13 December 2004
UCB's transition to biotechnology
13 December 2004
UCB Pharma introduces Keppra pregnancy registry
13 December 2004
UCB's Keppra effective in treating partial seizures in children; filing expected year-end
13 December 2004
UCB to transfer Japan Cinalong marketing rights to Kissei
22 November 2004
UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care
8 November 2004
UCB promotes Luc Missorten to CFO
25 October 2004
UCB divests chemicals to Cytec for 1.5 billion euros
11 October 2004
UCB partners with BWH for Parkinson's
4 October 2004
Positive new data for UCB's CDP-870 in RA
27 September 2004
Executive changes at UCB
13 September 2004
UCB sells French site to Nextpharma
6 September 2004
UCB reorganizes R&D operations
6 September 2004
Stock Commentary - Europe
16 August 2004
Stock Commentary - Europe
9 August 2004
UCB divests films business for 320 million euros
26 July 2004
Watson's oxybutynin patch gets EU OK
28 June 2004
Stock Commentary - Europe
31 May 2004
Stock Commentary - Europe
24 May 2004
Elan completes sale of Frova to Vernalis
24 May 2004
Celltech accepts L1.53 billin offer from UCB
24 May 2004
UK NICE guidance on insomnia drugs
10 May 2004
Stock Commentary - Europe
26 April 2004
Keppra sales data and Pfizer rumors boost UCB
19 April 2004
Vernalis pays Elan $55M for Frova return
5 April 2004
Keppra growth and a "buy" seen by UCB
29 March 2004
UK NICE backs newer antiepileptics
29 March 2004
Dr Reddy's files for US generic levetiracetam
29 March 2004
New chewable Zyrtec cleared by FDA
29 March 2004
UCB's Xyzal wins in head-to-head with S-P's Aerius
15 March 2004
Stock Commentary - Europe
15 March 2004
UCB's Keppra forges ahead
9 February 2004
Stock Commentary - Europe
5 January 2004
UCB Pharma's Keppra effective in controlling seizures in the elderly
22 December 2003
Keppra effective in brain tumor patients
8 December 2003
Fabrice Egros joins UCB Japan as president
10 November 2003
Stock Commentary - Europe
3 November 2003
Margaret Morgan joins UCB Pharma as head of communications
20 October 2003
Keppra effective in refractory epilepsy
20 October 2003
UCB names Roche Doliveux as DG, pharma sector
6 October 2003
Watson licenses novel product to UCB
6 October 2003
Stock Commentary - Europe
29 September 2003
UCB Pharma debuts Keppra in France
29 September 2003
New data for UCB Pharma's Keppra
15 September 2003
Stock Commentary - Europe
11 August 2003
French Council halts 10 drugs' support cuts
4 August 2003
UCB Pharma's Keppra solution gets FDA OK
28 July 2003
Stock Commentary - Europe
7 July 2003
Stock Commentary - Europe
23 June 2003
UCB inaugurates N America pharma HQ
26 May 2003
California directs HMOs over switched drugs
7 April 2003
UCB's Keppra gives pain relief in MS
31 March 2003
Canada approves UCB's Keppra
24 March 2003
Stock Commentary - Europe
10 March 2003
UCB-Bioproducts new synthetic peptide plant
3 March 2003
Zyrtec continues to drive UCB pharma
17 February 2003
Stock commentary - week to Feb 10 - Europe
17 February 2003
Stock commentary - week to Feb 10 - SPECTRUM
17 February 2003
Finland's Oriola takes over new drug distribution role
27 January 2003
UCB raises 2003 R&D investment 17%
13 January 2003
Relpax cleared in USA after four-year review
6 January 2003
Stock Commentary - Europe - 2 weeks to Dec 30
6 January 2003
UCB profits up 14% in 2nd quarter
12 August 2002
UCB starts trials of novel asthma compound
22 July 2002
Vernalis' Frova launched for migraine in USA
24 June 2002
French ruling against UCB over drug effects
3 June 2002
Stock Commentary - Europe
29 April 2002
Pfizer 1st-qtr EPS increases 18%
22 April 2002
Profits on the increase at Belgium's UCB Group
15 April 2002
BioFocus posts 95% sales increase
1 April 2002
Stock Commentary - Europe
18 March 2002
UCB not threatened by Claritin's OTC version
18 March 2002
UCB opens Asia-Pacific regional HQ in Malaysia
4 March 2002
Stock Commentary - Europe
4 March 2002
Zyrtec driving sales and earnings at UCB
18 February 2002
US HHS Sec backs "some" OTC switches
18 February 2002
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
